Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session -Gastrointestinal, non-colorectal

4525 - Pembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase 2 KEYNOTE-158 study

Date

19 Oct 2018

Session

Poster Discussion session -Gastrointestinal, non-colorectal

Presenters

Makoto Ueno

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

M. Ueno1, H.C. Chung2, A. Nagrial3, A. Marabelle4, R.K. Kelley5, L. Xu6, J. Mahoney6, S.K. Pruitt6, D. Oh7

Author affiliations

  • 1 Hepatobiliary And Pancreatic Oncology Division, Department Of Gastroenterology, Kanagawa Cancer Center, 241-0815 - Yokohama/JP
  • 2 Yonsei Cancer Center, Yonsei University College of Medicine, Seoul/KR
  • 3 Medical Oncology Specialists, Blacktown University of Sydney, 2148 - Sydney/AU
  • 4 Département D'innovation Thérapeutique Et D'essais Précoces, Gustave Roussy, Université Paris-Saclay, 94800 - Villejuif/FR
  • 5 Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 94143 - San Francisco/US
  • 6 Mrl, Merck & Co., Inc., 07033 - Kenilworth/US
  • 7 Department Of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, 110-744 - Seoul/KR
More

Resources

Abstract 4525

Background

Biliary tract cancers (BTC) are often diagnosed at an advanced stage, with standard gemcitabine plus cisplatin combination chemotherapy providing limited benefit. The phase 2, multicohort KEYNOTE-158 study (NCT02628067) evaluated antitumor activity and safety of pembrolizumab (pembro), an anti–PD-1 antibody in patients (pts) with advanced BTC.

Methods

Pts aged ≥18 y with histologically/cytologically confirmed unresectable or metastatic BTC and prior progression/intolerance on standard therapy were enrolled if they had measurable disease per RECIST v1.1, ECOG PS ≤ 1, and tumor sample for evaluation of PD-L1 (PD-L1 IHC 22C3 pharmDx assay [Agilent Technologies]) and other biomarkers. Pts received pembro 200 mg Q3W for up to 2 y or until disease progression or unacceptable AEs. The primary endpoint was ORR; DOR, PFS, OS and safety were secondary endpoints. Response was assessed every 9 wks in year 1, then every 12 wks (RECIST v1.1, independent central review). DOR, PFS, and OS were evaluated using the Kaplan-Meier method. AE severity was graded per NCI CTCAE v4.0. PD-L1 combined positive score (CPS; ≥1 or < 1) was determined.

Results

At data cutoff (Jan 15, 2018), 104 pts with BTC (49% male; median age, 63 y [range, 34–81]; ≥2 prior therapies, 52%) were enrolled (median follow-up, 9.3 mo [range, 0.6–23.6]). ORR was 5.8% (95% CI, 2.1–12.1; 6 PR, 0 CR); 17 pts (16%) had SD. Median DOR was not reached (range, 6.2–15.7+ mo); 2 pts had DOR ≥15 mo. ORR was 6.6% (95% CI, 1.8–15.9) and 2.9% (95% CI, 0.1–15.3) among those with PD-L1 CPS ≥1 (n = 61) and CPS <1 (n = 34), respectively. Median PFS was 2.0 mo (95% CI, 1.9–2.1) and median OS was 9.1 mo (95% CI, 5.6–10.4). Median PFS was 1.9 mo (95% CI, 1.8–2.0) vs 2.1 mo (95% CI, 1.9–2.6) and median OS was 7.2 mo (95% CI, 5.3–11.0) vs 9.6 mo (95% CI, 5.4–12.8) among pts with PD-L1 CPS ≥1 vs < 1, respectively. 99 pts (including all responders) were evaluated for MSI status; none were MSI-H. Overall, 55% of pts had treatment-related AEs (most commonly fatigue [14%], rash [12%], pruritus [9%]); 13% had grade 3–5 AEs, and 16% had immune-mediated AEs. Treatment-related AEs led to discontinuation in 6 pts.

Conclusions

Pembro shows durable antitumor activity in a subset of pts with advanced BTC regardless of PD-L1 CPS and had manageable toxicity.

Clinical trial identification

NCT02628067.

Legal entity responsible for the study

Merck Sharp & Dohme Corp.

Funding

Merck Sharp & Dohme Corp.

Editorial Acknowledgement

Medical writing and editorial assistance was provided by Sheri Arndt, PharmD, of C4 MedSolutions, LLC (Yardley, PA), a CHC Group company. This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Disclosure

M. Ueno: Honoraria and research funding: Taiho Pharmaceutical, Shire, AZ; Honoraria: Yakult Honsha, Novartis, Lilly, Teijin Pharma, Ono Pharmaceutical (OP); Research funding: Daiichi Sankyo, Eisai, OP, MSD, Merck Serono, NanoCarrier, Dainippon Sumitomo Pharma, Incyte. H.C. Chung: Consultant/advisor: Taiho, Celltrion, MSD, Lilly, Quintiles, BMS, Merck-Serono; Speaker: Merck-Serono, Lilly, Foundation Medicine; Research funding: Lilly, GSK, MSD, Merck-Serono, BMS-Ono, Taiho. A. Nagrial: Consultant/advisor for MSD, AstraZeneca, Shire; Speaker: AstraZeneca, Roche, BMS, MSD. A. Marabelle: Honoraria: Merck, BMS, Roche, Genentech; Research funding: Merus; Travel/accommodation: Roche, BMS, Amgen; Consultant/advisor: Roche, Genentech, Novartis, Amgen; Speaker: BMS, Amgen, Roche, Merck. R.K. Kelley: Advisory board: Bayer, Debiopharm Group; Steering committee: Agios, AZ, BMS; Research funding: Lilly, Exelixis, Regeneron, Celgene, Tekmira, Sanofi, Novartis, BMS, MedImmune, MSD, Agios, AZ, Adaptimmune, Taiho Pharmaceutical, Target Pharmasolutions, Bayer. L. Xu, S.K. Pruitt: Employee: Merck Sharp & Dohme Corp. J. Mahoney: Employee: ExecuPharm, King of Prussia, PA, USA, working under contract at Merck Sharp & Dohme Corp. D-Y. Oh: Research funding: AstraZeneca.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.